Vanguard Group’s TherapeuticsMD TXMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$647K Buy
397,056
+20,228
+5% +$29.2K ﹤0.01% 3887
2025
Q3
$399K Sell
376,828
-2,173
-0.6% -$2.44K ﹤0.01% 4000
2025
Q2
$440K Sell
379,001
-2,941
-0.8% -$3.56K ﹤0.01% 3947
2025
Q1
$353K Sell
381,942
-5,640
-1% -$5.62K ﹤0.01% 3964
2024
Q4
$333K Hold
387,582
﹤0.01% 4031
2024
Q3
$643K Hold
387,582
﹤0.01% 3908
2024
Q2
$624K Hold
387,582
﹤0.01% 3933
2024
Q1
$888K Hold
387,582
﹤0.01% 3855
2023
Q4
$872K Buy
387,582
+2,334
+0.6% +$5.63K ﹤0.01% 3876
2023
Q3
$1.16M Hold
385,248
﹤0.01% 3780
2023
Q2
$1.59M Hold
385,248
﹤0.01% 3739
2023
Q1
$1.44M Hold
385,248
﹤0.01% 3790
2022
Q4
$2.15M Buy
385,248
+124,837
+48% +$735K ﹤0.01% 3630
2022
Q3
$1.73M Sell
260,411
-105,383
-29% -$853K ﹤0.01% 3802
2022
Q2
$3.64M Buy
365,794
+16,830
+5% +$161K ﹤0.01% 3535
2022
Q1
$6.63M Sell
348,964
-53,624
-13% -$843K ﹤0.01% 3376
2021
Q4
$7.16M Buy
402,588
+24,372
+6% +$730K ﹤0.01% 3415
2021
Q3
$14M Buy
378,216
+5,992
+2% +$266K ﹤0.01% 3057
2021
Q2
$22.1M Buy
372,224
+10,397
+3% +$630K ﹤0.01% 2784
2021
Q1
$24.2M Buy
361,827
+98,514
+37% +$7.71M ﹤0.01% 2684
2020
Q4
$15.9M Buy
263,313
+7,859
+3% +$537K ﹤0.01% 2749
2020
Q3
$20.2M Buy
255,454
+4,067
+2% +$324K ﹤0.01% 2456
2020
Q2
$15.7M Sell
251,387
-88,412
-26% -$5.15M ﹤0.01% 2543
2020
Q1
$18M Buy
339,799
+7,894
+2% +$783K ﹤0.01% 2343
2019
Q4
$40.2M Buy
331,905
+39,512
+14% +$5.68M ﹤0.01% 2214
2019
Q3
$53.1M Buy
292,393
+1,139
+0.4% +$161K ﹤0.01% 2035
2019
Q2
$37.9M Buy
291,254
+15,770
+6% +$2.83M ﹤0.01% 2243
2019
Q1
$67.1M Buy
275,484
+9,574
+4% +$2.53M ﹤0.01% 1945
2018
Q4
$50.7M Buy
265,910
+8,029
+3% +$1.96M ﹤0.01% 2018
2018
Q3
$84.6M Buy
257,881
+23,075
+10% +$7.07M ﹤0.01% 1885
2018
Q2
$73.3M Buy
234,806
+6,921
+3% +$2.11M ﹤0.01% 1924
2018
Q1
$55.5M Sell
227,885
-192
-0.1% -$53.9K ﹤0.01% 2019
2017
Q4
$68.9M Buy
228,077
+9,874
+5% +$2.75M ﹤0.01% 1906
2017
Q3
$57.7M Buy
218,203
+13,581
+7% +$3.93M ﹤0.01% 1968
2017
Q2
$53.9M Buy
204,622
+8,585
+4% +$2.15M ﹤0.01% 1982
2017
Q1
$70.6M Buy
196,037
+10,319
+6% +$3.19M ﹤0.01% 1832
2016
Q4
$53.6M Buy
185,718
+4,290
+2% +$1.33M ﹤0.01% 1934
2016
Q3
$61.8M Buy
181,428
+6,425
+4% +$2.35M ﹤0.01% 1835
2016
Q2
$74.4M Buy
175,003
+59,887
+52% +$24.7M ﹤0.01% 1701
2016
Q1
$36.8M Buy
115,116
+13,535
+13% +$4.62M ﹤0.01% 2002
2015
Q4
$52.7M Buy
101,581
+5,882
+6% +$2.17M ﹤0.01% 1860
2015
Q3
$28M Buy
95,699
+16,003
+20% +$5.69M ﹤0.01% 2134
2015
Q2
$31.3M Buy
79,696
+3,533
+5% +$1.25M ﹤0.01% 2161
2015
Q1
$23M Buy
76,163
+9,116
+14% +$2.23M ﹤0.01% 2266
2014
Q4
$14.9M Buy
67,047
+5,192
+8% +$1.07M ﹤0.01% 2374
2014
Q3
$14.3M Buy
61,855
+5,576
+10% +$1.4M ﹤0.01% 2339
2014
Q2
$12.4M Buy
56,279
+3,095
+6% +$689K ﹤0.01% 2411
2014
Q1
$16.8M Buy
53,184
+12,915
+32% +$4.11M ﹤0.01% 2254
2013
Q4
$10.5M Buy
40,269
+17,714
+79% +$3.88M ﹤0.01% 2439
2013
Q3
$3.3M Buy
22,555
+1,587
+8% +$192K ﹤0.01% 2935
2013
Q2
$3.18M Buy
+20,968
New +$2.87M ﹤0.01% 2900

Other funds holding TXMD

Vanguard Group's TXMD Position: Q4 2025 in Review

Vanguard Group increased its TherapeuticsMD (TXMD) stake by 5.4% in Q4 2025, buying an estimated $29.2K and bringing the position to 397,056 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #3887.

Vanguard Group first reported a position in TXMD in Q2 2013 and has held it in 51 quarters since. The position peaked at $84.6M in Q3 2018. 44 funds tracked by Wall St. Rank hold TXMD as of Q4 2025.

  • Vanguard Group held 397,056 shares of TherapeuticsMD worth $647K as of Q4 2025.
  • Vanguard Group bought 20,228 TherapeuticsMD shares in Q4 2025, an estimated $29.2K.
  • TherapeuticsMD made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3887 holding.
  • Vanguard Group first reported a position in TherapeuticsMD in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's TherapeuticsMD position peaked at $84.6M in Q3 2018.
  • 44 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.